This content is machine translated Hodgkin's lymphoma Does brentuximab vedotin have curative potential in a subset of affected individuals? New results from a phase II study presented at the ASH Congress in New Orleans offer hope for patients with refractory or relapsed Hodgkin’s lymphoma: Approximately 10% of participants in…
